Cargando…
Insights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary?
Anaplastic lymphoma kinase (ALK) has been identified to exert a potent transforming activity through its rearrangement in non-small cell lung cancer (NSCLC), and patients (pts) with ALK rearrangement can be treated more successfully with ALK inhibitors, such as crizotinib, alectinib, and ceritinib,...
Autores principales: | Toyokawa, Gouji, Seto, Takashi, Takenoyama, Mitsuhiro, Ichinose, Yukito |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4661196/ https://www.ncbi.nlm.nih.gov/pubmed/26342831 http://dx.doi.org/10.1007/s10555-015-9592-y |
Ejemplares similares
-
Lorlatinib-Induced Pulmonary Embolism in a Patient With an ALK-Positive NSCLC
por: Toyozawa, Ryo, et al.
Publicado: (2020) -
Short progression‐free survival of ALK inhibitors sensitive to secondary mutations in ALK‐positive NSCLC patients
por: Haratake, Naoki, et al.
Publicado: (2019) -
Uncommon features of surgically resected ALK-positive cavitary lung adenocarcinoma: a case report
por: Takamori, Shinkichi, et al.
Publicado: (2017) -
Recurrence of thymic neuroendocrine carcinoma 24 years after total excision: A case report
por: TOYOKAWA, GOUJI, et al.
Publicado: (2013) -
Clinicopathological features of younger (aged ≤ 50 years) lung adenocarcinoma patients harboring the EML4‐ALK fusion gene
por: Kometani, Takuro, et al.
Publicado: (2018)